DNATRIX INC
DNX-2440, a tumor-selective oncolytic adenovirus encoding OX40 ligand for cancer immunotherapy
- Sector
- Biotech
- Headquarters
- Houston, TX
- Latest Form D
- $15.5M, Sep 2018
- Total capital
- $32.4M
- Federal grants
- $1.7M
- 2 awards · 2022
- Rank in peer group#39 of 502
- Private capital raised
- $30.7M
- 4 Form D · last Sep 2018
- 97 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 6 pending · first 2018
- Rank in peer group#41 of 502
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Phase 1 Study of DNX-2440 for Resectable Colorectal Liver Metastasis - IND 018569$853K
- Federal grantHealth and Human S · Phase II · Phase 1 Study of DNX-2440 for Resectable Colorectal Liver Metastasis - IND 018569$853K
- Private capital raisedForm D · SEC · 4th filing$15.5M
- Private capital raisedForm D · SEC · 3rd filing$12.8M
- Private capital raisedForm D · SEC · 2nd filing$1.5M
- Private capital raisedForm D · SEC · 1st filing$886K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grants#39 · top 8%
- Granted patents#41 · top 8%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Frank TufaroResearcherExecutive Officer, DirectorLinked by 1 patent
- Brian Patrick MooneyExecutive OfficerNamed in SEC Form D filings
- Daniel M. WatkinsExecutive Officer, DirectorNamed in SEC Form D filings
- Drew Patrick PardollDirectorNamed in SEC Form D filings
- Francis Patrick McCormickDirectorNamed in SEC Form D filings
- Imre Patrick KovesdiExecutive Officer, DirectorNamed in SEC Form D filings
Show all 8 people
- Isaac Patrick ChengDirectorNamed in SEC Form D filings
- Reenie Patrick McCarthyDirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 8- GrantedCombination Therapy For Treatment Of Brain CancersUSPTOUS 11,110,137
- PendingCombination Therapy For Treatment Of Brain CancersUSPTOApplication 16346310
- PendingOncolytic Adenoviruses For Cancer TreatmentUSPTOApplication 16028037
Show all 8 patent records
- Combination Therapy For Treatment Of Brain CancersSep 7, 2021 · US 11,110,137Granted
- Combination Therapy For Treatment Of Brain CancersSep 12, 2019 · Application 16346310Pending
- Oncolytic Adenoviruses For Cancer TreatmentJun 20, 2019 · Application 16028037Pending
- Oncolytic Adenoviruses for Cancer TreatmentJul 10, 2018 · US 10,016,470Granted
- Oncolytic Adenoviruses for Cancer TreatmentMar 12, 2015 · Application 14327840Pending
- Combination Therapy For Treatment Of Brain CancersApplication PCTUS2017059611Pending
- Use Of Oncolytic Adenovirus For The Treatment Of Pediatric Brain CancerApplication 63179899Pending
- Adenovirus Expressing Immune Cell Stimulatory Receptor Agonist(s)Application PCTUS2014066920Pending
Related companies, and why
- CANCURE LLCSimilar federal contract value in Biotech · null in contracts
- PETAOMICS, INC.Similar federal contract value in Biotech · null in contracts
- ARISAPH PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
- PROTAGONIST THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- TATEVA THERAPEUTICS INC.Similar federal contract value in Biotech · null in contracts
- DFI Holding Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .